These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 12843632)

  • 1. Therapeutic effect of camostat mesilate on Duchenne muscular dystrophy in mdx mice.
    Sawada H; Nagahiro K; Kikukawa Y; Ban S; Kakefuda R; Shiomi T; Yokosawa H
    Biol Pharm Bull; 2003 Jul; 26(7):1025-7. PubMed ID: 12843632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Deflazacort Treatment on the Functioning of Skeletal Muscle Mitochondria in Duchenne Muscular Dystrophy.
    Dubinin MV; Talanov EY; Tenkov KS; Starinets VS; Belosludtseva NV; Belosludtsev KN
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33228255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
    Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
    FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catalpol counteracts the pathology in a mouse model of Duchenne muscular dystrophy by inhibiting the TGF-β1/TAK1 signaling pathway.
    Xu DQ; Zhao L; Li SJ; Huang XF; Li CJ; Sun LX; Li XH; Zhang LY; Jiang ZZ
    Acta Pharmacol Sin; 2021 Jul; 42(7):1080-1089. PubMed ID: 32939036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy.
    Mantuano P; Sanarica F; Conte E; Morgese MG; Capogrosso RF; Cozzoli A; Fonzino A; Quaranta A; Rolland JF; De Bellis M; Camerino GM; Trabace L; De Luca A
    Biochem Pharmacol; 2018 Aug; 154():89-103. PubMed ID: 29684379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
    Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
    J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amitriptyline is efficacious in ameliorating muscle inflammation and depressive symptoms in the mdx mouse model of Duchenne muscular dystrophy.
    Manning J; Kulbida R; Rai P; Jensen L; Bouma J; Singh SP; O'Malley D; Yilmazer-Hanke D
    Exp Physiol; 2014 Oct; 99(10):1370-86. PubMed ID: 24972834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy.
    Ahmad A; Brinson M; Hodges BL; Chamberlain JS; Amalfitano A
    Hum Mol Genet; 2000 Oct; 9(17):2507-15. PubMed ID: 11030755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein-Anchoring Therapy of Biglycan for Mdx Mouse Model of Duchenne Muscular Dystrophy.
    Ito M; Ehara Y; Li J; Inada K; Ohno K
    Hum Gene Ther; 2017 May; 28(5):428-436. PubMed ID: 27485975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deletion of Galgt2 (B4Galnt2) reduces muscle growth in response to acute injury and increases muscle inflammation and pathology in dystrophin-deficient mice.
    Xu R; Singhal N; Serinagaoglu Y; Chandrasekharan K; Joshi M; Bauer JA; Janssen PM; Martin PT
    Am J Pathol; 2015 Oct; 185(10):2668-84. PubMed ID: 26435413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of trypsin-like proteases and protease nexin-1 in mdx mouse muscles.
    Sawada H; Kikukawa Y; Ban S; Kakudo T; Yokosawa H
    Biochem Biophys Res Commun; 2004 Feb; 314(2):654-8. PubMed ID: 14733957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bowman-Birk inhibitor attenuates dystrophic pathology in mdx mice.
    Morris CA; Selsby JT; Morris LD; Pendrak K; Sweeney HL
    J Appl Physiol (1985); 2010 Nov; 109(5):1492-9. PubMed ID: 20847128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Murine models of Duchenne muscular dystrophy: is there a best model?
    Swiderski K; Lynch GS
    Am J Physiol Cell Physiol; 2021 Aug; 321(2):C409-C412. PubMed ID: 34260298
    [No Abstract]   [Full Text] [Related]  

  • 15. Green tea extract and its major polyphenol (-)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophy.
    Dorchies OM; Wagner S; Vuadens O; Waldhauser K; Buetler TM; Kucera P; Ruegg UT
    Am J Physiol Cell Physiol; 2006 Feb; 290(2):C616-25. PubMed ID: 16403950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of alpha 7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy.
    Guo C; Willem M; Werner A; Raivich G; Emerson M; Neyses L; Mayer U
    Hum Mol Genet; 2006 Mar; 15(6):989-98. PubMed ID: 16476707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent PTH treatment improves bone and muscle in glucocorticoid treated Mdx mice: A model of Duchenne Muscular Dystrophy.
    Yoon SH; Grynpas M; Mitchell J
    Bone; 2019 Apr; 121():232-242. PubMed ID: 30716510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy.
    Gehrig SM; van der Poel C; Hoeflich A; Naim T; Lynch GS; Metzger F
    Growth Horm IGF Res; 2012 Apr; 22(2):69-75. PubMed ID: 22424862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenic impairment of the vascular endothelium: a novel mechanism and potential therapeutic target in muscular dystrophy.
    Palladino M; Gatto I; Neri V; Straino S; Smith RC; Silver M; Gaetani E; Marcantoni M; Giarretta I; Stigliano E; Capogrossi M; Hlatky L; Landolfi R; Pola R
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2867-76. PubMed ID: 24072696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased plasma lipid levels exacerbate muscle pathology in the mdx mouse model of Duchenne muscular dystrophy.
    Milad N; White Z; Tehrani AY; Sellers S; Rossi FMV; Bernatchez P
    Skelet Muscle; 2017 Sep; 7(1):19. PubMed ID: 28899419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.